Loading...
Market
How many new NSAA-based therapies will GRO Biosciences add to its pipeline by July 19, 2025?
2
GRO Biosciences•Atlas Venture•Access Biotechnology•Leaps by Bayer•Redmile Group•Digitalis Ventures•iEndeavors•Pillar•Dan
Resolution / Starting Odds
1-2 new therapies • 25%
3-4 new therapies • 25%
5 or more new therapies • 25%
No new therapies • 25%
Press releases from GRO Biosciences, company announcements
Story
GRO Biosciences Secures $60.3M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 19, 2024, 12:05 PM
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.
View original story
Similar markets
None • 25%
1-3 targets • 25%
4-6 targets • 25%
More than 6 targets • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
1-3 drugs/vaccines • 25%
4-6 drugs/vaccines • 25%
7-9 drugs/vaccines • 25%
10 drugs/vaccines • 25%
Autoimmune diseases • 25%
Neurological disorders • 25%
Metabolic disorders • 25%
Other therapeutic areas • 25%